Penile cancer: Clinical Practice Guidelines in Oncology

Autor: Pe, Clark, Pe, Spiess, Agarwal N, Mc, Biagioli, Ma, Eisenberger, Re, Greenberg, Hw, Herr, Brant Inman, Da, Kuban, Tm, Kuzel, Sm, Lele, Michalski J, Pagliaro L, Sk, Pal, Patterson A, Er, Plimack, Ks, Pohar, Mp, Porter, Jp, Richie, Wj, Sexton, Wu, Shipley, Ej, Small, Dl, Trump, Wile G, Tg, Wilson, Dwyer M, Ho M, National Comprehensive Cancer Network

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN, vol 11, iss 5
Europe PubMed Central

Squamous cell carcinoma of the penis represents approximately 0.5% of all cancers among men in the United States and other developed countries. Although rare, it is associated with significant disfigurement, and only half of the patients survive beyo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::45f74b36421d90ce911e21a5393f1bde
https://escholarship.org/uc/item/53d840zs

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).

Autor: Geynisman DM; Fox Chase Cancer Center, Philadelphia, PA., Abbosh PH; Fox Chase Cancer Center, Philadelphia, PA., Ross E; Fox Chase Cancer Center, Philadelphia, PA., Zibelman MR; Fox Chase Cancer Center, Philadelphia, PA., Ghatalia P; Fox Chase Cancer Center, Philadelphia, PA., Anari F; Fox Chase Cancer Center, Philadelphia, PA., Mark JR; Thomas Jefferson University Hospital, Philadelphia, PA., Stamatakis L; MedStar Washington Hospital Center, Washington D.C., Hoffman-Censits JH; Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins)., Viterbo R; Fox Chase Cancer Center, Philadelphia, PA., Greenberg RE; Fox Chase Cancer Center, Philadelphia, PA., Churilla TM; Fox Chase Cancer Center, Philadelphia, PA., Horwitz EM; Fox Chase Cancer Center, Philadelphia, PA., Hallman MA; Fox Chase Cancer Center, Philadelphia, PA., Smaldone MC; Fox Chase Cancer Center, Philadelphia, PA., Uzzo R; Fox Chase Cancer Center, Philadelphia, PA., Chen DYT; Fox Chase Cancer Center, Philadelphia, PA., Kutikov A; Fox Chase Cancer Center, Philadelphia, PA., Plimack ER; Fox Chase Cancer Center, Philadelphia, PA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 16, pp. JCO2401214. Date of Electronic Publication: 2024 Dec 16.

Real-time estimation of nephron activity with a linear measurement system (RENAL-MS) predicts postoperative estimated glomerular filtration rate.

Autor: Schober JP; Division of Urologic Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA., Ginsburg KB; Department of Urology, Wayne State University, Detroit, MI, USA., Kutikov A; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Cho EY; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Loecher M; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Strauss D; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Castro Bigalli AA; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Handorf E; Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA., Deng M; Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA., Anaokar J; Department of Diagnostic Radiology, Fox Chase Cancer Center, Philadelphia, PA, USA., Chen DYT; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Greenberg RE; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Smaldone MC; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Viterbo R; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Correa AF; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Uzzo RG; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Strother M; Department of Urology, Oregon Health and Science University, Portland, OR, USA.

Publikováno v: BJU international [BJU Int] 2024 Feb; Vol. 133 (2), pp. 206-213. Date of Electronic Publication: 2023 Oct 02.

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.

Autor: Hahn NM; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA. Electronic address: nhahn4@jhmi.edu., O'Donnell MA; University of Iowa Carver College of Medicine, Iowa City, IA, USA., Efstathiou JA; Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Zahurak M; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Rosner GL; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Smith J; Hoosier Cancer Research Network, Indianapolis, IN, USA., Kates MR; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Bivalacqua TJ; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Division of Urology and Urologic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Tran PT; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA., Song DY; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Baras AS; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Matoso A; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Choi W; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Smith KN; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA., Pardoll DM; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA., Marchionni L; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins University School of Medicine, Center for Computational Genomics, Baltimore, MD, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., McGuire B; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Grace Phelan M; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Johnson BA 3rd; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., O'Neal T; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., McConkey DJ; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Division of Medical Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., Bjurlin M; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Urology, University of North Carolina, Chapel Hill, NC, USA., Lim EA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Spectrum Health Medical Group, Grand Rapids, MI, USA., Drake CG; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Janssen Research and Development, Springhouse, PA, USA., McKiernan JM; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Urology, Columbia University, New York, NY, USA., Deutsch I; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Radiation Oncology, Columbia University, New York, NY, USA., Anderson CB; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Urology, Columbia University, New York, NY, USA., Lamm DL; BCG Oncology, Phoenix, AZ, USA., Geynisman DM; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Plimack ER; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Hallman MA; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Al-Saleem E; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA., Chen DYT; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Greenberg RE; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Kutikov A; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Guo G; Department of Radiation Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, USA; University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Masterson TA; Department of Urology, Indiana University Simon Cancer Center, Indianapolis, IN, USA., Adra N; Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, USA., Kaimakliotis HZ; Department of Urology, Indiana University Simon Cancer Center, Indianapolis, IN, USA.

Publikováno v: European urology [Eur Urol] 2023 Jun; Vol. 83 (6), pp. 486-494. Date of Electronic Publication: 2023 Jan 28.

Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.

Autor: Zhang E; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Ruth KJ; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Buyyounouski MK; Department of Radiation Oncology, Stanford University, Stanford, California., Price RA Jr; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Uzzo RG; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Sobczak ML; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Pollack A; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida., Wong JK; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Chen DYT; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Hallman MA; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Greenberg RE; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Watkins-Bruner D; Emory University, Atlanta, Georgia., Al-Saleem T; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: eric.horwitz@fccc.edu.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2023 Apr 01; Vol. 115 (5), pp. 1074-1084. Date of Electronic Publication: 2022 Dec 23.